Posted by Michael Wonder on 15 Feb 2021
Targovax receives fast track designation for ONCOS-102
15 February 2021 - Targovax today announces that its lead clinical candidate ONCOS-102 has received fast track designation in malignant pleural mesothelioma from the US FDA.
The US FDA granted fast track designation to ONCOS-102 based on encouraging pre-clinical and clinical efficacy associated with broad immune activation observed to date.
